FindTrial
Sign In

Prospective application of MiniPDX assays in individualized treatment of Luminal breast cancer

Prospective application of MiniPDX assays in individualized treatment of Luminal breast cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800017901
Enrollment
Unknown
Registered
2018-08-20
Start date
2018-10-01
Completion date
Unknown
Last updated
2018-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Group 1:treating according to the results of MiniPDX susceptibility test
Group 2:Treating patients with traditional chemotherapy

Sponsors

Zhongshan Hospital Fudan university
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. pathological diagnosis of patients with Luminal type of advanced breast cancer; 2. The expected survival time is greater than 3 months; 3. I or the client agree to join the study and voluntarily provide relevant personal information, organization samples, etc. for the study; 4. PKS score > 60 points, comprehensive assessment of patients who are able to tolerate chemotherapy and targeted therapy.

Exclusion criteria

Exclusion criteria: 1. unable to or refuse to collect tumor samples, including tumor tissue blocks, or malignant hydrothorax and ascites, or circulating tumor cells; 2. Refuse to accept the relevant treatment plan or follow-up plan;

Design outcomes

Primary

MeasureTime frame
PFS;OS;—

Countries

China

Contacts

Public ContactZhang Hongwei

Zhongshan Hospital Fudan university

zhang.hongwei@zs-hospital.sh.cn+86 13386057198

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026